CAS 191217-81-9 Pramipexole Treating Parkinson’ S and Bipolar Depression

China CAS 191217-81-9 Pramipexole Treating Parkinson’ S and Bipolar Depression, Find details about China Pramipexole, OEM Nootropics from CAS 191217-81-9 Pramipexole Treating Parkinson’ S and Bipolar Depression

Model NO.
PX-A
CAS
84371-65-3
Sample
Free
Usage
API
Product Nane
Mifepristone
Colour
White
Appearance
White Powder
Supply
Bulk
Trademark
OEM
Transport Package
25kg/Drum
Specification
25KG/Bag
Origin
China
HS Code
3001200010
Model NO.
PX-A
CAS
84371-65-3
Sample
Free
Usage
API
Product Nane
Mifepristone
Colour
White
Appearance
White Powder
Supply
Bulk
Trademark
OEM
Transport Package
25kg/Drum
Specification
25KG/Bag
Origin
China
HS Code
3001200010
Product Description

CAS 191217-81-9 Pramipexole Treating Parkinson’ S and Bipolar Depression

CAS 191217-81-9 Pramipexole Treating Parkinson’ S and Bipolar Depression

 
Product NamePramipexole dihydrochloride monohydrate
AppearanceWhite or off- white crystalline powder
Assay99%min, 98.0% --101.0%
TestHPLC 
CertificateISO 9001 
CAS191217-81-9
MFC10H21Cl2N3OS
Storage TemperatureCool Dry Place
Pramipexole dihydrochloride
Pramipexole dihydrochloride CAS No.: 191217-81-9
Pramipexole dihydrochloride Molecular Formula: C10H19Cl2N3S
Pramipexole dihydrochloride Molecular Weight: 284.25
Pramipexole dihydrochloride Melting point: 288-290°C
Pramipexole dihydrochloride Appearance: white crystalline powder
Standard: Enterprise Standard
Packing: 25KG/Drum or as per your requirements
Pramipexole dihydrochloride Application: Parkinson's syndrome
Category:  Antiparkinsonian;All Inhibitors;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;APIs;Chiral Reagents;Sulfur Compounds;Parkinson's disease drug;pharmaceutical raw material;intermediate;API
 
Pramipexole dihydrochloride Use:

To alleviate the symptoms of Parkinson's disease: Parkinson's disease is due to the movement of brain dopaminergic neuron loss caused by dopamine deficiency, lead to patients with tremor, rigidity and bradykinesia and a series of symptoms. highly selective effects on dopamine D2 and D3 receptor agonist, dopamine release, improve motor symptoms. Research on Shannon display, early Parkinson's disease patients pramipexole monotherapy after, can effectively control the motor symptoms in patients with early stage, to help maintain the ability of daily life. Pramipexole in combination with levodopa can effectively improve the ADL score and motor symptoms in patients with advanced Parkinson's disease score in patients with advanced Parkinson's disease, make life more vibrant.
Detailed Photos
CAS 191217-81-9 Pramipexole Treating Parkinson’ S and Bipolar Depression
CAS 191217-81-9 Pramipexole Treating Parkinson’ S and Bipolar Depression

 

Our Advantages

CAS 191217-81-9 Pramipexole Treating Parkinson’ S and Bipolar Depression